UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2014-04, Vol.28 (4), p.438-453

2014

Volltextzugriff (PDF)

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin

British journal of dermatology (1951), 2009-02, Vol.160 (2), p.319-324

2009

Volltextzugriff (PDF)

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

British journal of dermatology (1951), 2011-05, Vol.164 (5), p.1091-1096

2011

Volltextzugriff (PDF)

Aldara®-induced skin inflammation: studies of patients with psoriasis

British journal of dermatology (1951), 2015-02, Vol.172 (2), p.345-353

2015

Volltextzugriff (PDF)

Definition of treatment goals for moderate to severe psoriasis: a European consensus

ARCHIVES OF DERMATOLOGICAL RESEARCH, 2011-01, Vol.303 (1), p.1-10

2011

Volltextzugriff (PDF)

Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice

British journal of dermatology (1951), 2016-05, Vol.174 (5), p.1011-1021

2016

Volltextzugriff (PDF)

Strategies for improving the quality of care in psoriasis with the use of treatment goals - a report on an implementation meeting

Journal of the European Academy of Dermatology and Venereology, 2011-05, Vol.25 (s3), p.1-13

2011

Volltextzugriff (PDF)

Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp

Journal of the European Academy of Dermatology and Venereology, 2014-05, Vol.28 (s2), p.10-21

2014

Volltextzugriff (PDF)

The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin

British journal of dermatology (1951), 2005-01, Vol.152 (1), p.37-42

2005

Volltextzugriff (PDF)

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

Journal of the European Academy of Dermatology and Venereology, 2009-12, Vol.23 (12), p.1374-1382

2009

Volltextzugriff (PDF)

Topical corticosteroids in psoriasis: strategies for improving safety

Journal of the European Academy of Dermatology and Venereology, 2010-02, Vol.24 (2), p.119-124

2010

Volltextzugriff (PDF)

Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy

British journal of dermatology (1951), 2010-12, Vol.163 (6), p.1194-1204

2010

Volltextzugriff (PDF)

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris

British journal of dermatology (1951), 2006-06, Vol.154 (6), p.1155-1160

2006

Volltextzugriff (PDF)

Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study

Archives of Dermatological Research, 2013-12, Vol.305 (10), p.899-907

2013

Volltextzugriff (PDF)

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study

British journal of dermatology (1951), 2010-08, Vol.163 (2), p.402-411

2010

Volltextzugriff (PDF)

The expression of dual-specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin

British journal of dermatology (1951), 2013-02, Vol.168 (2), p.339-345

2013

Volltextzugriff (PDF)

Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis

Journal of the European Academy of Dermatology and Venereology, 2017-02, Vol.31 (2), p.294-303

2017

Volltextzugriff (PDF)

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet((R))/Daivobet((R))/Taclonex((R))) in the treatment of psoriasis vulgaris

British journal of dermatology (1951), 2006-06, Vol.154 (6), p.1155

2006

Volltextzugriff (PDF)

Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial

British journal of dermatology (1951), 2009-07, Vol.161 (1), p.159-166

2009

Volltextzugriff (PDF)

Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement

British journal of dermatology (1951), 2010-06, Vol.162 (6), p.1216-1223

2010

Volltextzugriff (PDF)

Scalp psoriasis: a review of current topical treatment options

Journal of the European Academy of Dermatology and Venereology, 2007-10, Vol.21 (9), p.1151-1160

2007

Volltextzugriff (PDF)

The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis

British journal of dermatology (1951), 2005-11, Vol.153 (5), p.911-918

2005

Volltextzugriff (PDF)

Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression

Inflammation research, 2011-07, Vol.60 (7), p.643-653

2011

Volltextzugriff (PDF)

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

British journal of dermatology (1951), 2013-02, Vol.168 (2), p.374-380

2013

Volltextzugriff (PDF)

Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model

British journal of dermatology (1951), 2009-02, Vol.160 (2), p.284-296

2009

Volltextzugriff (PDF)

1 – 25 von 335

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(284)
Mit Volltextzugriff
(258)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

Aldara®-induced skin inflammation: studies of patients with psoriasis

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice

Strategies for improving the quality of care in psoriasis with the use of treatment goals - a report on an implementation meeting

Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp

The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

Topical corticosteroids in psoriasis: strategies for improving safety

Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris

Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study

The expression of dual-specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin

Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet((R))/Daivobet((R))/Taclonex((R))) in the treatment of psoriasis vulgaris

Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial

Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement

Scalp psoriasis: a review of current topical treatment options

The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis

Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model

Suchergebnisse filtern